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ORIGINAL ARTICLE
Mutant p53 enhances MET trafficking and signalling to drive
cell scattering and invasion
PAJ Muller1, AG Trinidad1, P Timpson1, JP Morton1, S Zanivan1, PVE van den Berghe1, C Nixon1, SA Karim1, PT Caswell2, JE Noll3,
CR Coffill4, DP Lane5, OJ Sansom1, PM Neilsen3, JC Norman1 and KH Vousden1
Tumour-derived mutant p53 proteins promote invasion, in part, by enhancing Rab coupling protein (RCP)-dependent receptor
recycling. Here we identified MET as an RCP-binding protein and showed that mutant p53 promoted MET recycling. Mutant p53-
expressing cells were more sensitive to hepatocyte growth factor, the ligand for MET, leading to enhanced MET signalling, invasion
and cell scattering that was dependent on both MET and RCP. In cells expressing the p53 family member TAp63, inhibition of
TAp63 also lead to cell scattering and MET-dependent invasion. However, in cells that express very low levels of TAp63, the ability
of mutant p53 to promote MET-dependent cell scattering was independent of TAp63. Taken together, our data show that mutant
p53 can enhance MET signalling to promote cell scattering and invasion through both TAp63-dependent and -independent
mechanisms. MET has a predominant role in metastatic progression and the identification of mechanisms through which mutations
in p53 can drive MET signalling may help to identify and direct therapy.
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INTRODUCTION
The p53 tumour suppressor protein has a critical role in
preventing malignant progression and is mutated in more than
half of all human cancers, frequently resulting in the expression of
p53 proteins that carry a single amino acid substitution. The
majority of these mutations affect the central DNA-binding
domain of p53 and lead to the loss of wild-type p53 functions,
such as the ability to promote cell cycle arrest and apoptosis in
response to oncogenic stress. However, several of these p53
mutants, including the hotspot mutants R175H and R273H, show a
gain of oncogenic function in driving invasion and metastasis.1–3
This novel gain of function is related, at least in part, to the ability
of mutant p53 to cause changes in gene expression.4,5 Mutant p53
controls the expression of various genes both directly6–8 and
indirectly by interfering with the function of other transcription
factors, including NF-Y, VDR and the p53 family members p63 and
p73.6,9–11 Various molecules can enhance or antagonize the
function of mutant p53 in regulating these transcription factors,
including TopBP1, Pin1 and ANKRD11.12–14 The ability of mutant
p53 to regulate the activity of TAp63 is particularly interesting, as
TAp63 can function as a suppressor of tumour development and
metastasis15,16 and can regulate the expression of anti-metastatic
genes, such as Dicer,16 Cyclin G2 and Sharp-1.17 However, it is
clear that mutant p53 can also function through TAp63-
independent mechanisms12,18 and mutant p53 drives invasive
behaviour in cells that do not express detectable TAp63.19,20
We found previously that one consequence of mutant p53
expression is the increased recycling and signalling of integrins
and EGFR (epidermal growth factor receptor)20 mediated by Rab
coupling protein (RCP), which itself can act as an oncogene in
breast cancers.21 Similar effects were induced by depletion of
TAp63, suggesting that one mechanism by which mutant p53
functions is by preventing this function of TAp63.
In this study, we show that RCP-dependent MET (the receptor
for hepatocyte growth factor, HGF) signalling is enhanced by
mutant p53 expression, resulting not only in increased invasion
but also in cell scattering. In cells expressing TAp63, this activity
can be mediated through inhibition of TAp63, although mutant
p53 also shows p63-independent activities. The importance of
MET recycling in tumorigenesis has recently been demonstrated
for tumour-derived MET mutants.22 However, our work is the first
to demonstrate the importance of RCP in MET signalling and the
modulation of this mechanism by mutant p53.
RESULTS
Mutant p53 expression promotes cell scattering
Several studies have shown that the ability of mutant p53 to
promote enhanced metastasis in mouse models is paralleled by
enhanced invasion of mutant p53-expressing cells in various tissue
culture systems. To examine the effects of mutant p53 expression
on cell growth characteristics, we generated a p53 null small cell
lung cancer cell line (H1299) tagged with green fluorescent
protein (GFP) and a mutant p53 (273H)-expressing H1299 cell line
tagged with Cherry. Co-culture of p53 273H and control cells
showed that the mutant p53 cells did not grow in colonies, but
adopted a more scattered appearance compared with empty
vector cells (red compared with green cells in Figure 1a). Using
Ecdysone inducible (EI) H1299 cells, in which ponasterone
A (ponA) can induce expression of either the 175H or 273H
mutant p53 to levels observed for MDA MB231 cells that express
endogenous mutant p53 (Supplementary Figure S1a), we found
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Figure 1. Mutant p53 enhances MET signalling to drive scattering. (a) Merged red and green channel microscope images and bright field
images of control (EV) and mutant p53 (273H) H1299 cells tagged with, respectively, GFP or Cherry. Scale bars indicate 50 mm. (b) EI H1299 cells
expressing a vector (ctr) or mutant p53 (175H or 273H) were allowed to form discrete colonies. A total of 2.5 mg/ml ponA was then added to
the cells and scattering was monitored using time lapse microscopy. Scale bars indicate 20 mm. (c) Immunostaining for ZO-1, PAR3, DAPI and a
merge (left panels) or p53 (right panels) in EI 175H cells after ponA induction. Scale bars indicate 10 mm. Arrows indicate PAR3 staining in the
cell–cell junctions. (d) EI 175H cells were transfected with MET siRNA and after 16 h induced with ponA or HGF for 48 h and analysed for
scattering (left panels, quantification right panels). Knockdown of MET was verified using immunoblot analysis for MET expression (middle
panel) with GCN5 as loading control. Scale bars indicate 50 mm. * indicates statistical significant changes (Po0.05) as determined by a T-test.
(e) Mutant p53 (175H or 273H) or control (EV) H1299 cells were analysed for MET expression and MET phosphorylation as assessed by western
blot using different pMET antibodies with or without 10min HGF stimulation. Total MET and actin were used as loading control.
(f ) Immunoblot analysis showing MET phosphorylation in EI 175H H1299 cells uninduced (none) or induced to express mutant p53 (ponA),
incubated with HGF for 0.5, 1, 2, 4 or 10min. Actin and total MET expression were used as loading controls. (g) ELISA measurement of HGF
excretion in the medium of ponA-treated EI 175H cells. Ctr indicates medium that has not been exposed to cells. Pos indicates a positive HGF
lysate as included in the ELISA kit.
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that induction of either p53 mutant resulted in dissociation of
established cell colonies (Figure 1b), an effect that was not seen in
the EI control cells lacking mutant p53. Although we were unable
to detect either of the most commonly expressed adherens
junction proteins, E-Cadherin or P-Cadherin, in H1299 cells, tight
junctions proteins, such as ZO-123 and PAR3,24 were detected at
points of cell–cell contacts. PonA induction in EI 175H cells
(Figure 1c) and EI 273H cells, but not EI ctr cells (Supplementary
Figure S1b), led to a time-dependent loss of both ZO-1 and PAR3
from the cellular junctions that coincided with increased nuclear
mutant p53 expression.
The ability of mutant p53 to promote dissociation or
‘scattering’25,26of epithelial cell colonies is reminiscent of the
effect of activation of the MET receptor by its ligand HGF.
The scattering of H1299 cells in response to mutant p53 was
similar to that seen following treatment of cells with HGF
(Figure 1d), although mutant p53 was somewhat less potent than
HGF in inducing this response. Furthermore, HGF and ponA
treatment decreased levels of ZO-1 at cellular junctions
(Supplementary Figure S1b). Both mutant p53- and HGF-induced
scattering (Figure 1d) and loss of ZO-1 from cell junctions
(Supplementary Figure S1c) was dependent on MET expression,
suggesting that signalling through MET is important for the
scattering response to mutant p53. Importantly, the reduction in
mutant p53-induced scattering resulting from small interfering
RNA (siRNA)-mediated depletion of MET was rescued by MET
overexpression, confirming the specificity of MET knockdown
(Supplementary Figure S1d). By contrast, EGF treatment of
control cells did not induce either scattering (Supplementary
Figure S1e) or loss of ZO-1 from cellular junctions (Supplementary
Figure S1f). Furthermore, inhibition of the EGFR with PD153035
did not prevent HGF- or mutant p53-induced driven scattering
(data not shown), indicating that EGFR activity is not required for
scattering.
Mutant p53 enhances MET activation and promotes MET recycling
The scattering behaviour of cells in response to mutant p53
expression prompted us to test whether mutant p53-
expressing cells showed any increase in MET activation. Using
H1299 cells stably expressing mutant p53, we found that the
activating phosphorylations on tyrosine residues within
the catalytic domain of MET (1230–1235) were enhanced in
mutant p53 (175H and 273H) cells (Figure 1e). Mutant p53
expression also increased the sensitivity of cells to phosphoryla-
tion on these sites following treatment with exogenous
HGF (Figure 1e). This enhanced phosphorylation was much less
apparent when using an antibody that recognizes phosphoryla-
tion of MET at residue Y1003, which is a negative regulatory site
(Figure 1e). Similarly, induction of mutant p53 by ponA treatment
in the inducible H1299 cells resulted in enhanced phosphorylation
of MET and increased sensitivity to HGF stimulation (Figure 1f).
Notably, although both wild-type p53 and mutant p53 have been
shown to regulate MET transcription and expression,27,28
we did not observe a mutant p53-induced change in total
MET protein levels under these conditions. Furthermore,
mutant p53 expression did not increase HGF secretion by H1299
cells, although we were able to detect a basal level of HGF
production in these cells (Figure 1g). Taken together, the
data indicate that expression of mutant p53 enhances the
sensitivity of MET to HGF, either produced by the cell or added
to the medium.
Our previous studies demonstrated that mutant p53 can
promote EGFR signalling by enhancing receptor recycling through
an RCP-dependent mechanism. Using a SILAC-based approach to
identify proteins co-immunoprecipitating with RCP in control and
mutant p53-expressing H1299 cells, we confirmed the interaction
of RCP with a5b1 integrin and the enhancement of this by mutant
p53 (Figure 2a). As seen previously, RCP also binds to EGFR,
although this interaction was not enhanced in mutant
p53-expressing cells.20 Interestingly, among the proteins that
were detected, we identified MET as a novel RCP-binding protein
(Figure 2a, right panel). Like EGFR, the interaction of MET with
RCP was not enhanced by mutant p53, and we were able to
confirm the interaction in independent co-immunoprecipitation
experiments (Figure 2b). The interaction of MET with RCP
suggested that, like EGFR, MET may be recycled to the cell
surface in mutant p53-expressing cells. Indeed, internalized MET
and a5 integrin were recycled to the plasma membrane more
rapidly in mutant p53 cells than in control cells (Figure 2c). By
analogy with previous observations with the EGFR, mutant p53-
dependent enhanced recycling of MET would be predicted to
result in enhanced MET activation and scattering. Indeed, we were
able to show that both the sensitivity of mutant p53-expressing
cells to HGF-induced MET phosphorylation (Figure 2d) and the
scattering of mutant p53-expressing cells (Figure 2e) were
dependent on RCP. Importantly, induction of cell scattering
through direct depletion of cell junction proteins, such as ZO-1
and PAR3, was not opposed by RCP depletion (Figure 2f),
demonstrating a specificity of the requirement of RCP in mutant
p53-induced scattering.
Mutant-p53 expressing cells show enhanced MET-dependent
signalling
To determine whether signalling downstream of MET was
enhanced in mutant p53-expressing cells, we examined MAPK
activation.29,30 Induction of mutant p53 (in EI 175H cells) resulted
in an increase in ERK1/2 phosphorylation compared with control
cells, and enhanced ERK1/2 phosphorylation in response to HGF
treatment (Figure 3a). A titration of ponA revealed a dose-
dependent increase in ERK1/2 phosphorylation in response to p53,
although again no increase in overall MET or ERK1/2 proteins
were detected (Supplementary Figure S2a). Similarly, transient
expression of either 175H or 273H mutant p53 constructs
enhanced ERK1/2 phosphorylation (Supplementary Figure S2b).
Mutant p53 also enhances EGFR signalling, but importantly we
were able to show that the induction of ERK1/2 phosphorylation
was largely dependent on MET in these cells, as MET depletion
substantially reduced phospho-ERK1/2 accumulation (Figure 3a).
In H1299 cells stably expressing mutant p53, the basal levels of
phospho-ERK1/2 were the same as those seen in p53 null control
cells (Figure 3b), suggesting that prolonged growth in culture
stimulates the known negative feedback mechanisms function to
limit ERK1/2 activation.31 However, mutant p53-expressing cells
retained enhanced sensitivity to exogenous HGF, showing
enhanced phosphorylation of ERK1/2 that was blunted by MET
depletion (Figure 3b) or treatment with a MET inhibitor
(Supplementary Figure S2c). Treatment of cells with a MEK
inhibitor to inhibit ERK1/2 phosphorylation blocked both HGF
and mutant p53-driven cell scattering (Figure 3c), demonstrating
the importance of ERK1/2 signalling to this response. To
determine whether mutant p53 signals leads to activation of
ERK1/2 phosphorylation in vivo, we stained sections of xenografts
that had been generated by injecting H1299-EV and H1299 p53
273H cells in the mammary fat pad of mice20 for pERK1/2
expression (Figure 3d). H1299 p53 273H xenografts showed more
staining that was localized primarily at the invasive front of the
tumour. In a pancreatic ductal carcinoma (PDAC) mouse model,
gain-of-function expression of mutant p53 with K-Ras mutation
has previously been shown to result in liver metastases,32 which
are not seen from tumours arising in the absence of p53. Sections
of pancreatic tumours originating from p53172H/172H and p53loxp/
loxp mice showed the most intense pERK1/2 expression in almost
all tumours derived from mutant p53 mice (Figure 3e). More
importantly, cell lines derived from the mutant p53 PDAC had
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increased basal pERK1/2 levels and increased phosphorylation of
both MET and ERK1/2 after HGF exposure (Figure 3f). Together
these data demonstrate that mutant p53 can enhance MET-
dependent ERK1/2 phosphorylation, resulting in enhanced scat-
tering and invasion.
Mutant p53 drives MET-dependent invasion
Previously we showed that mutant p53 promotes the ability of
cells to invade through Matrigel towards EGF by promoting RCP-
dependent increased recycling of a5b1 integrin and EGFR.20 As
both EGFR and MET signalling have been shown to contribute to
Figure 2. RCP-dependent recycling of MET contributes to MET signalling in mutant p53 cells. (a) Mutant p53 (273H) or control (EV) H1299 cells
were SILAC-labelled with ‘light’, ‘medium’ or ‘heavy’ amino acids and transfected with GFP or GFP-RCP as indicated in the left diagram. Cells
were lysed and a co-immunoprecipitation with GFP was used to precipitate RCP-binding proteins. Quantitative mass spectrometry data
analysis revealed a ratio of RCP-binding proteins in EV cells and 273H cells compared with GFP-transfected EV cells (comparison 1 and 2), or
differential binding to RCP in 273H cells compared with EV cells (comparison 3, right table). (b) MET co-immunoprecipitation with RCP in EV
control or 273H H1299 cells that were transfected with GFP or GFP-RCP. Cell lysates were immunoprecipitatedfor GFP and analysed for MET
binding as assessed by immunoblot analyses for MET. (c) Recycling assays for alpha 5 integrin and MET in EV and 273H H1299 cells. * indicates
statistical significant changes (Po0.05) as determined by a T-test. (d) Immunoblot analysis showing MET phosphorylation in mutant p53
(273H) H1299 that were transfected with siRNA targeting RCP and incubated with HGF for indicated times. Actin and total MET expression
were used as loading controls. (e) Scattering of EI 175H cells that were transfected with RCP siRNA and after 16 h induced with ponA (2.5 mg/
ml) for 48 h (left panel). Scale bars indicate 50 mm. Knockdown of RCP expression and expression of p53 after ponA (2.5mg/ml) induction was
verified by western blot analysis using actin as a loading control (right panel). (f ) Quantification of scattering of EI 175H cells that were
transfected with RCP siRNA in combination with or without ZO-1 or PAR3 siRNA and after 16 h induced with ponA for 48 h.
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invasion,33 we examined the ability of mutant p53 expression to
influence the invasive behaviour of cells in Matrigel using HGF as
an attractant. These assays showed increased invasion of mutant
p53 cells towards either EGF or HGF (Figure 4a) and induction of
mutant p53 in the ponA-inducible cell line also led to increased
invasion towards HGF (Figure 4b and Supplementary Figure S3a).
IGF-1 (insulin-like growth factor) or PDGF-b (platelet-derived
growth factor-b) were unable to enhance the invasive behaviour
of mutant p53-expressing cells (Supplementary Figure S3b),
although the cells were responsive to both growth factors as
demonstrated by AKT phosphorylation (Supplementary Figure
S3c). Interestingly, the IGF-1-R and PDGF-b-R were not detected as
RCP-binding partners in our SILAC analysis, suggesting some
specificity in the receptor tyrosine kinases that are influenced by
RCP and therefore targets for mutant p53. The increased invasion
of mutant p53 cells towards HGF was dependent on MET
(Figure 4c) and a5b1 integrin (Figure 4d) function. Importantly,
the increased invasion (although not basal invasion) seen in
mutant p53-expressing cells was also lost following RCP depletion
(Figure 4e). These data indicate that RCP-mediated recycling of
integrin and MET is required for the enhanced invasiveness of
mutant p53 cells. Notably, loss of ZO-1 or PAR3 (which led to cell
scattering, Figure 2f) also resulted in enhanced invasion of empty
vector (EV) cells, suggesting that loss of cell–cell junctions can at
least partially contribute to the invasion of mutant p53 cells
(Figure 4f).
MET and EGFR share several downstream signalling targets and
crosstalk between these two receptors has been demonstrated to
enhance proliferation, invasion and scattering.34–36 This prompted
us to investigate whether mutant p53 specifically increased
Figure 3. ERK1/2 phosphorylation is required for mutant p53-dependent scattering and invasion. (a) Activation of ERK1/2 in EI 175H cells using
phospho-specific ERK1/2 antibodies was determined after induction of mutant p53 with ponA for 24 h. Total ERK1/2 levels are shown as
control for equal ERK1/2 expression in all samples and GCN5 was used as loading control. The numbers indicate quantification of pERK1/2
levels as compared with ctr cells transfected with ctr siRNA and not treated with HGF and normalized for total ERK1/2 levels. (b) Activation of
ERK1/2 after HGF stimulation in p53 273H and control EV H1299 cells, assessed by western blot using a pERK1/2 antibody. The numbers
indicate quantification of pERK1/2 levels as compared with EV cells transfected with ctr siRNA and not treated with HGF and normalized for
total ERK1/2 levels. (c) Scattering of EI 175H cells 48 h after ponA, HGF and/or U0126 treatment. Scale bars indicate 50 mm. pERK1/2 expression
is shown (right panel) with ERK1/2 and actin as loading controls. (d) Staining of pERK1/2 in xenografts of H1299 EV (8 mice) and 273H cells (7
mice) (left panels). pERK1/2 staining was divided into four intensity categories ranging from 0 for no staining and 3 for the highest intensity.
The percentage of staining per category at the invasive edge of the tumour in each section was analysed and the overall percentage of
staining for each score is depicted in the table. (e) Immunohistochemical images for pERK1/2 and p53 levels in p53 null and mutant p53 172H
(mouse equivalent of human 175H) pancreatic tumours. The scoring indicates the strength of the immunohistochemical signal in which 0 is
no staining and 3 is the highest signal. Scale bars indicate 100 mm. The table indicates the numbers of tumours of independent mice in which
each score was found. (f ) MET and ERK1/2 phosphorylation in cell lines established from the p53 null or mutant p53 (172H) pancreatic
tumours after HGF treatment. Total MET, total ERK1/2 and actin were used as loading controls.
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Figure 4. Mutant p53 promotes MET-dependent invasion towards HGF. (a) Mutant p53 (273H) or control (EV) H1299 cells were analysed for
invasion capacity in fibronectin-supplemented Matrigel using EGF or HGF as a chemo-attractant (left panel). Invasion was quantified as described
in the Materials and methods section and values are means±s.e.m. of six replicates from each of three independent experiments (right panel).
*indicates statistical significant changes (Po0.05) as determined by a T-test. (b) EI 175H H1299 cells were analysed for invasion capacity in
fibronectin-supplemented Matrigel using HGF as a chemo-attractant after induction with increasing doses of ponA. Invasion was quantified as
described in the Materials and methods section and values are means±s.e.m. of six replicates from each of three independent experiments (right
panel). * indicates statistical significant changes (Po0.05) as determined by a T-test. (c) Mutant p53 (273H) or control (EV) H1299 cells were
analysed for invasion after knockdown of MET using HGF as a chemo-attractant. * indicates statistical significant changes (Po0.05) as determined
by a T-test. Knockdown of MET was verified by western blot (right panel), using GCN5 as a loading control. (d) Mutant p53 (273H) or control (EV)
H1299 cells were analysed for invasion capacity in fibronectin-supplemented Matrigel with monoclonal antibodies against a5 integrin, using HGF
as a chemo-attractant. * indicates statistical significant changes (Po0.05) as determined by a T-test. (e) Mutant p53 (273H) or control (EV) H1299
cells were transfected with RCP siRNA and analysed for invasion capacity in fibronectin-supplemented Matrigel using HGF as a chemo-attractant.
Knockdown of RCP was verified by western blot using actin as loading control (right panel). * indicates statistical significant changes (Po0.05) as
determined by a T-test. (f ) H1299 EV cells were transfected with siRNA against ZO-1 or PAR3 and compared with 273H cells for invasion capacity in
fibronectin-supplemented Matrigel using HGF as chemo-attractant. * indicates statistical significant changes (Po0.05) as determined by a T-test.
(g) 3D reconstructive images of 273H H1299 cells invading towards EGF or HGF. (h) MDA MB231 cells were transfected with siRNA-targeting
(mutant) p53 and analysed for invasion capacity into fibronectin-supplemented Matrigel using HGF as chemo-attractant (middle panel).
Knockdown was verified by western blot using actin as loading control (left panel). Quantified invasion is shown in the right panel.
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signalling via MET to enhance invasion towards HGF, or whether
this reflected concurrent activation of the EGFR. Treatment of cells
with the EGFR inhibitor PD153035 resulted in an overall decrease
in cell invasion towards HGF, but the difference in invasion
between mutant p53 and control cells was unaffected
(Supplementary Figure S3d). Therefore, although EGFR signalling
contributes to the basal invasive activity of these cells, enhanced
HGF-driven invasion promoted by mutant p53 requires MET, but
not EGFR signalling. Interestingly, a clear difference in the invasion
of mutant p53 cells promoted by the two growth factors was
evident in 3D images of invading cells, with HGF promoting more
extensive invasion and also more branched invasive structures
(Figure 4g and Supplementary Movies S1a and S1b). To confirm
that endogenous mutant p53 also enhanced invasion towards
HGF, we repeated the assay using MDA MB231 cells (expressing
R280K p53). These cells invaded efficiently towards HGF, an
activity that was strongly inhibited following depletion of the
endogenous mutant p53 (Figure 4h).
Endogenous mutant p53 can modulate MET-dependent scattering
and invasion
To address the role of endogenous mutant p53 in regulating the
scatter process, we used HT29 cells and A431 cells (both of
which express endogenous p53 273H). These cells express
E-cadherin37,38 and form tight colonies under normal growth
conditions. In response to high levels of HGF, the cells
scatter30,39 (Figures 5a and c) and E-cadherin is lost from the cell
junctions (Supplementary Figures S4a and S4b). siRNA-mediated
depletion of the endogenous mutant p53 resulted in a decrease in
the ability of these cells to scatter in response to HGF (Figures 5a
and c) and the retention of E-cadherin and ZO-1 at the cell
junctions after prolonged HGF treatment (Supplementary Figures
S4a and S4b). To quantify this effect, we made Z-stacks of A431
and HT29 colonies and measured the height of the E-cadherin
staining at the junctions in cells that were treated with HGF. It is
important to note that for these experiments we looked at a time
point prior to cell scattering. At these early times following HGF
treatment, control cells showed a clear reduction in the height of
E-cadherin staining in response to HGF, which was impaired by
depleting mutant p53 (Figures 5b and d). Furthermore, A431 cells
depleted of endogenous mutant p53 showed decreased MET
phosphorylation in response to HGF (Figure 5e), which is
consistent with our results in H1299 cells. Consistent with these
cell models, cells derived from mutant p53-expressing PDAC
tumours scattered better after HGF exposure compared with cells
from p53 null tumours (Figure 5f). Expression of the human
mutant p53 constructs 175H and 273H in the cells derived from
the p53  / PDAC tumours also enhanced scattering
(Figure 5g), invasion into organotypic assays (Figure 5h) and
phosphorylation of ERK1/2 and MET in response to HGF (Figure 5i),
indicating that our observations are not the result of hetero-
geneity of the pancreatic tumours or clonal selection of PDAC
cells.
The role of TAp63 in mediating mutant p53 activities
Several functions of mutant p53 have been attributed to the
ability to bind and inhibit the activity of p53 family members p63
and p73. Indeed, loss of the TA isoform of p63 has been shown to
drive invasion and metastasis in a manner very similar to that seen
in response to mutant p53 expression.16,40 Our previous studies
showed that depletion of p63, but not p73, promoted invasion of
H1299 cells towards EGF, and we found a similar effect of p63
depletion on the ability of these cells to invade towards HGF
(Figure 6a). Neither mutant p53 expression nor loss of p63
promoted invasion in general towards medium without additional
growth factors (Supplementary Figure S5a). The invasion pro-
moted by p63 depletion was also dependent on MET expression
(Figure 6b). In MDA MB231 cells, where depletion of the
endogenous mutant p53 inhibited invasion towards HGF, deple-
tion of p63 had no effect on overall invasion (Figure 6c). However,
loss of p63 rescued the invasive behaviour in cells depleted of
mutant p53 (Figure 6c). Turning to cell scattering in H1299 cells,
we observed scattering in Cherry-tagged control cells after
knockdown of p63, similar to that seen in the GFP-tagged mutant
p53 cells (Figure 6d). Consistently, reduced expression of p63 in
control cells using a pool of siRNA (Figure 6e) or single siRNA
(Supplementary Figure S5b) resulted in scattering similar to that
observed following mutant p53 induction (Figure 6e). The
scattering induced by loss of p63 in these cells was also MET
and RCP dependent (Figure 6f). Taken together, the results
support a model in which mutant p53 functions to inhibit the
activity of p63, and that either expression of mutant p53 or
depletion of p63 promotes invasion and cell scattering through an
RCP-dependent mechanism.
To examine the relationship between mutant p53-induced
scattering and the inhibition of p63 more closely, we tested a
number of cell lines for patterns of p63 expression. There is some
lack of consensus in the literature concerning which isoforms of
p63 are expressed in which cell lines, inconsistencies that may
reflect drift of different clones of these established cells lines. In
our hands (Figure 7a), both H1299 and MDA MB231 cells
expressed the TA isoforms of p63, with no detectable expression
of DNp63 (TAp63 expression in H1299 cells has been confirmed by
others).41 By contrast, we found that A431 and HT29 cells
expressed very low levels of TAp63, with high levels of DNp63
expression in A431 cells (as previously described42 (Figure 7a).
However, despite this very low level of TAp63 expression, both
A431 and HT29 cells showed mutant p53-dependent scattering
(Figure 4). Depletion of p63 did not alter the scattering of these
cells in response to HGF (Figure 7b, c and d) but, surprisingly,
depletion of p63 did not reverse the inhibition of scattering
following depletion of mutant p53 in either cell line (Figure 7b, c
and d), suggesting that mutant p53 can function independently of
p63. We therefore turned to the colorectal carcinoma HCT116 cell
lines, in which we were unable to detect expression of any p63
isoform (Figure 7a). Lack of p63 expression in these cells has been
described by others, although TAp63 expression can be induced
by treatment with the HDAC inhibitor TSA.43 Mutant p53-
dependent scattering was also observed in these cells, where
we compared cells null for p53 with those engineered to express
mutant p53 (Figure 7e). Although the null cells formed very tight
colonies that were not responsive to HGF, the mutant p53 cells
formed looser colonies with many elongated cells, which scattered
in response to HGF (Figure 7e). Consistent with our observation in
other cells lines, these cells showed a mutant p53-dependent
enhanced activation of MET in response to HGF (Figure 7f). Finally,
siRNA-mediated depletion of mutant p53 and MET in the mutant
p53-expressing HCT116 cells inhibited scattering in response to
HGF, confirming the specificity of mutant p53 driving this
scattering via MET (Figure 7g).
Taken together, these results indicate that whereas mutant p53
can function through the inhibition of p63 in cells expressing
TAp63, the effects of mutant p53 on cell invasion and scattering
can also be mediated by p63-independent mechanisms.
DISCUSSION
The activation of MET has been particularly associated with
metastatic behaviour of tumours44 and silencing of MET in
established metastases using lentiviral RNAi approaches has
been shown to lead to tumour regression in mice.45 MET is a
receptor tyrosine kinase (RTK) that has a role in various cellular
processes, including proliferation, invasion and cell scattering. The
ability of MET signalling to induce cell scattering has been well
established in the MDCK canine cell line46 and we show here that
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several human cell lines derived from various tumour types scatter
in response to HGF in a mutant p53-dependent manner.
Furthermore, we show that whereas cell lines derived from
invasive pancreatic tumours that harbour a p53 mutation scatter
in response to HGF, non-invasive p53 null cancers do not show
this phenotype. These results suggest the scattering process
induced in response to mutant p53 expression might have a role
in cancer metastasis in vivo. The enhanced recycling of the MET
receptor has previously been shown to promote ERK activation
and cell migration47 and oncogenic mutant MET shows enhanced
Figure 5. Endogenous mutant p53 also promotes scattering. (a and c) Scattering images of HT29 cells (a) or A431 (c) after transfection with
control siRNA or p53 siRNA in the presence of 30 ng/ml HGF for 48 h (upper panels). Scale bars indicate 50 mm. Knockdown of p53 was verified
by western blot using actin as loading control (bottom panels). (b and d) Ortho-images of Z-stacks of overlay immune fluorescence of HT29 (b)
and A431 (d) cells, with views of XY (centre image), XZ (above centre image) or YZ (right of centre image) axes. Cells were transfected with
control siRNA or p53 siRNA, then treated or not with 30 ng/ml HGF for 16 h and the height of E-Cadherin staining in cell junctions is shown
(right panels). p53 (red), E-cadherin (green), DAPI (blue) and scale bars indicate 10 mm. * indicates statistical significant changes (Po0.05) as
determined by a T-test. (e) Immunoblot analysis showing MET phosphorylation in A431 cells transfected with siRNA-targeting (mutant) p53
and incubated with HGF for indicated times. Actin and total MET expression were used as loading controls. (f ) Scattering of cell lines
established from the p53 null and mutant p53 (172H) pancreatic tumours after HGF treatment for 48 h. Scale bars indicate 50 mm. Scattering
(g), invasion in organotypic assays (h) and MET/ ERK1/2 phosphorylation (i) in response to HGF of cell lines established from the p53 null
pancreatic tumours that were stably transfected with human mutant p53 175H and 273H. Scale bars indicate 50 mm. Total MET, total ERK1/2
and actin were used as loading controls.
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trafficking and signalling.22 Our data reveal another mechanism
for oncogenic MET activation in the absence of mutations in MET,
which occurs as a response to mutant p53 expression.
The intersection of p53 and MET signalling has been proposed
by several previous studies that demonstrated an ability of wild-
type p53 function to control MET expression. Whereas MET has
been reported as target for transcriptional activation by p53,28
other studies have shown that wild-type p53 suppresses
expression of MET, both through direct repression of the MET
promoter and indirectly through enhanced expression of miR-
34.48 Although mutant p53 proteins were shown to retain some
ability to repress MET expression in ovarian surface epithelial
cells,27 we were unable to detect a clear effect of mutant p53 in
altering the overall levels of MET in cells lacking wild-type p53.
These observations may reveal dissociation between MET mRNA
and protein levels. Indeed, it is possible that in the longer term the
effects of p53 on MET recycling may lead to its accumulation (and
other similarly regulated receptors such as the EGFR) by
interfering with the normal internalization and lysosomal
degradation of the activated receptors. Taken together, the data
suggest that in most cell types loss of wild-type p53 results in
increased MET expression, whereas expression of mutant p53
further sensitizes cells to enhance MET signalling by promoting its
RCP-dependent recycling. Importantly, our results show the
mutant p53-driven recycling of MET results in enhanced
sensitivity to HGF either in basal medium (where the only HGF
available is that secreted by the cells) or in response to addition of
HGF to the medium. Although we see enhanced activation of
ERK1/2 in mutant p53-expressing cells, it is not yet clear whether
this RCP-dependent signalling is qualitatively the same as the
response of cells to high levels of HGF in all respects. We
previously described differential phosphorylation of EGFR in
mutant p53 cells that distinguished this signal from that seen in
response to EGF.20 RTK activation consists of a series of events that
include (auto) phosphorylation, dimerization, decreased
dephosphorylation and decreased degradation, followed by the
concerted action of numerous different signalling molecules that
bind RTKs and subsequently determine the cellular response.49
Differential modification and activation of downstream signalling
cascades in response to different stimuli has been described for
these receptors, and the exact consequences of mutant p53 on
further downstream events remain to be determined.
Although we have shown that recycling and signalling from
both the EGFR and MET are enhanced by mutant p53, mutant
p53-expressing cells did not show enhanced invasion in response
to PDGF-b or IGF-1. These results illustrate some degree of
selectivity in either mutant p53- or RCP-driven receptor recycling,
although it seems possible that other RTKs will be regulated in the
Figure 6. Effect of p63 depletion on cell scattering and invasion. (a) Mutant p53 (273H) or control (EV) H1299 cells were transfected with p63
siRNA and analysed for their invasion capacity to HGF as chemo-attractant. To verify knockdown of p63, relative p63 mRNA expression levels
are shown in the right panel. * indicates statistical significant changes (Po0.05) as determined by a T-test. (b) Analysis of invasion of EV cells
transfected with a combination of p63 and MET siRNA compared with 273H cells using HGF as chemo-attractant. (c) MDA MB231 cells were
analysed for invasion capacity in fibronectin-supplemented Matrigel after knockdown of (mutant) p53 and/or p63, using HGF as chemo-
attractant. * indicates statistical significant changes (Po0.05) as determined by a T-test. (d) Fluorescence images of co-cultures of H1299 cells
expressing mutant p53 273H and GFP with empty vector (EV) cells expressing Cherry, following transfection of p63 siRNA. Scale bars indicate
50mm. (e) EI 175H cells were transfected with p63 or ctr siRNA and incubated in ponA (2.5 mg/ml) as indicated. After 48 h, scattering was
quantified. * indicates statistical significant changes (Po0.05) as determined by a T-test. Scale bars indicate 50 mm. (f ) H1299 cells were
transfected with MET or RCP siRNA in combination with p63 siRNA and quantified for scattering 48 h later. * indicates statistical significant
changes (Po0.05) as determined by a T-test.
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same way as both the EGFR and MET, and so contribute to the
response to mutant p53. We are presently analysing the
contribution to enhanced invasion and tumorigenesis that is
made by several additional RTKs that were found to be associated
with RCP in our mass spectrometry analysis. As knockdown of RCP
can prevent invasion and scattering, future work will focus on
understanding this process and the possibilities of inhibiting RCP
as a means of therapy.
Figure 7. Mutant p53 regulates scattering via p63-dependent and -independent mechanisms. (a) p63 isoform expression in H1299, MDA
MB231, A431, HT29 and HCT116 cells using isoform-specific oligos and quantitative RT–PCR. Expression is compared with expression of the
TAp63 isoform in H1299 cells and corrected for GAPDH expression in each cell line. (b) Images of scattering of HT29 cells that were transfected
with siRNA against (mutant) p53 and/or p63 and after 16 h incubated in HGF for 48 h. (c) Quantification of scattering of HT29 cells that were
transfected with siRNA against (mutant) p53 and/or p63 and after 16 h incubated in HGF for 48 h. (d) Quantification of scattering of HT29 cells
that were transfected with siRNA against (mutant) p53 and/or p63 for 16 h and incubated in HGF for 48 h. (e) HCT 116  / or HCT 248W/
cells were analysed for scattering after HGF treatment for 48 h. (f ) HCT116 248W/ cells were transfected with p53 siRNA, serum starved for
1 h and incubated with HGF as indicated. pMET and p53 levels were analysed by western blot, total MET and actin were used as loading
control. (g) HCT116  / or HCT248W/ cells were transfected with siRNA against p53 or MET for 16 h and analysed for scattering after HGF
treatment for 48 h (left panels). Knockdown of MET and p53 was verified by western blot as indicated in the right panel. Actin was used as
loading control.
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Mutant p53s function through a number of mechanisms,
including control of transcription by direct binding to regulatory
regions of target genes, indirect modulation of gene expression
through interaction with other transcription factors and transcrip-
tionally independent activities that reflect the interaction of p53
with other proteins.50,51 Through these mechanisms, mutant p53
controls numerous responses, including cell survival, migration,
invasion, autophagy and metabolism. The ability of mutant p53 to
inhibit the activity of TAp63 is appealing as a mechanism to
promote invasion, as depletion or deletion of TAp63 promotes
many of the invasive phenotypes also seen in response to mutant
p53.17,20,40 We show here that regulation of TAp63 by mutant p53
contributes to the cell’s scattering response in those cells that
retain TAp63 expression. However, the scattering activity of
mutant p53 in cells that have low or no detectable TAp63 is
mediated by functions that are distinct from the ability to inhibit
p63. This may reflect any of the other reported activities of mutant
p53 and highlights the recognition of numerous, potentially
independent, activities of mutant p53 that contribute to
phenotypes such as enhanced invasion and metastasis. It is
clear that the final cell response to mutant p53 expression will
reflect the integration of a plethora of signals that are both p63
dependent and independent.
From a clinical perspective, the ability of mutant p53 to
promote both EGFR and MET trafficking and signalling is an
interesting finding, because both receptors have been reported to
be activated in various cancers, and combination strategies in vivo
and in vitro to inhibit both receptors have been found to be more
effective than inhibition of only one.52–55 Thus, the identification
of RTKs that are activated by mutant p53 may highlight
combinations of inhibitors that would be particularly effective in
the treatment of mutant p53-expressing cancers.
MATERIALS AND METHODS
Cell culture, generation of PDAC cell lines and constructs
H1299 cells, HT29, MDA-MB-231 and A431 cells were obtained from ATCC
and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen,
Paisley, UK) supplemented with 10% FCS (fetal calf serum) and 1%
glutamine at 37 1C and 5% CO2. HCT116 p53 null and HCT116 248W cells
were described previously.56 The EI system was previously described57 and
cells were established as described in Noll et al.13 Stable cell lines and
mutant p53 constructs were generated as described previously.20 GFP and
Cherry constructs were purchased from BD biosciences, Clontech (Oxford,
UK). Cells were authenticated by morphology and Mycoplasma detection in
accordance with the ATCC cell line verification test recommendations.
Primary mouse PDACs were derived from tumours harvested from Pdx1-Cre-
GFP, LSL-KRasG12D/þ , Trp53LoxP/þ mice.32 p53 null PDAC cells were subsequently
transfected with empty vector, mutant p53R175H or mutant p53R273H using
Polyfect as described by manufacturer’s protocol (Qiagen, Crawley, UK). Cells
were selected using 0.6mg/ml G418 and stable pools generated using standard
procedures. Cell lines were cultured in DMEM (Invitrogen) supplemented with
10% FBS (fetal bovine serum) and 2mM L-glutamine (Invitrogen).
Cell transfections
The following oligos were used for siRNA experiments: control siRNA (1)
50-GCAACGGCAUUCCACCUUU(TT)-30 , ctr siRNA (2) control pool Dharmacon
(D-001810-10-20), RCP (smartpool Dharmacon, L-015968-00-0005), EGFR
smartpool Dharmacon (L-003114-00-0010), p53 50-GACUCCAGUGGUAAU
CUAC(TT)-30 , p63 (1) 50-UGAACAGCAUGAACAAGCU(TT)-30 and p63 (2) 50-UG
ACUUCAACUUUGACAUG(TT)-30 , MET (smartpool Dharmacon, L-003156-00-0
005). ZO-1 (1) 50-GGAAACAGCUAUAUGGGAA(TT)-30 , ZO-1 (2) 50-GCCUGUGUA
UGCCCAAGUU(TT)-30 , PAR3 (1) 50-CCAGGGAAUUUCUGACAUU(TT), PAR3 (2)
50-GCGUGACUAUGCUGAAAUU(TT)-30 . Cells were transfected with siRNA
using Hiperfect (Qiagen) or nucleofection (Lonza, Slough, UK). For hiperfect,
30pmol of a pool of two siRNA oligos or smartpool siRNA from Dharmacon
was combined with 7.5ml Hiperfect in 800ml of serum-free DMEM for six-well
plates. This mixture was vortexed and incubated for 10min before adding to
cells grown for 24h in six-well dishes in normal medium. All siRNAs were
tested separately for efficient knockdown in immuno blot analysis or
quantitative RT–PCR and potential off-target effects. For Amaxa nucleofec-
tion, 120pmol siRNA was transfected per 1 107 cells using solution T and
program X-001 for H1299 and A431 cells and X-023 for HT-29 cells (Lonza).
For overexpression, lipofectamine (Invitrogen), effectene (Qiagen) or
Genejuice (Merck Biosciences, Nottingham, UK) were used according to the
manufacturer’s protocols.
SILAC-based mass spectrometry
H1299 EV and H1299 273H cells were grown in SILAC DMEM (PAA) 10%
FBS (10 KDa dialysed, PAA), supplemented with light — L-arginine (Arg0)
and L-lysine (Lys0) — medium — L-arginine-U-13C6 (Arg6) and L-lysine
2H4
(Lys4) — or heavy — L-arginine-U-13C6
15N4 (Arg10) and L-lysine-U-
13C6-
15N2
(Lys8) — amino acids (Cambridge Isotope Laboratories, Cambridge, UK).
EV cells were labelled in light or medium DMEM. Mutant p53 273H cells
were labelled in heavy. Cells were cultured for 48 passages until an
incorporation of497% of medium and heavy amino acids was measured.
Cells were subsequently transfected with GFP or GFP-RCP and lysed.
Immunoprecipitations were performed as described previously,58 with
the addition that antibodies were cross-linked to the beads. Briefly,
magnetic beads conjugated to sheep anti-mouse IgG (Invitrogen) were
bound to mouse-anti-GFP (Abcam, Cambridge, UK). Antibody-coated
beads were washed twice (0.2 M Sodium Borate, 0.1% NP-40, pH 9.0)
prior to cross-linking with 25mM DMP (dimethyl pimelimidate
dihydrochloride) (in 0.2 M Sodium Borate, 0.1% NP-40, pH 9.0) for 45min
at room temperature. Beads were washed once (0.2 M Sodium Borate, 0.1%
NP-40, pH 9.0) and primary amines were blocked with 0.2 M ethanolamine
(phosphate-buffered saline (PBS), pH 8.0 and 0.1% NP-40) for 1 h at room
temperature. Beads were washed briefly with 100mM glycine pH 2.5 and
neutralized with 50mM Tris–Hcl pH 7.4, 0.1% NP-40. Lysates were pre-
cleared with magnetic beads conjugated to sheep anti-mouse IgG, and
antibody-coated beads were incubated with 8mg lysate per condition for
2 h at 4 1C with constant rotation. Unbound proteins were removed by
extensive washing in lysis buffer, and specifically associated proteins were
eluted from the beads by boiling for 10min in Laemmli sample buffer.
Proteins were resolved by SDS–PAGE and analysed by western blotting as
described previously.59 For mass spectrometry analysis, proteins were gel-
digested60 and peptides were analysed on a LTQ-Orbitrap Velos equipped
with nanoelectrospray source (Thermo Fisher Scientific, Basingstoke, UK).
Peptides and proteins were identified and quantified using the MaxQuant
software61 and searched with the Andromeda search engine62 against the
human IPI database 3.68.62
Organotypic assays
Organotypic assays were done as described previously.63 Briefly,
B7.5 104/ml primary human fibroblasts were embedded in a 3D
(three-dimensional) matrix of rat tail collagen I. Rat tail tendon collagen
solution was prepared by the extraction of tendons with 0.5 M acetic acid
to a concentration ofB2mg/ml. Detached, polymerized matrix (2.5ml) in
35mm petri dishes was allowed to contract for approximately 6 days in
complete media (DMEM, supplemented with 10% FCS, Invitrogen) until the
fibroblasts had contracted the matrix to B1.5 cm diameter. Subsequently,
4 104 PDAC cells were plated on top of the matrix in complete media
and allowed to grow to confluence for 5 days. The matrix was then
mounted on a metal grid and raised to the air/liquid interface resulting in
the matrix being fed from below with complete media that was changed
every 2 days. After 8–12 days, the cultures were fixed using 4%
paraformaldehyde and processed by standard methods for hematoxylin
and eosin staining. Representative images of at least three independent
experiments are shown.
Scattering assays
For live cell imaging, 2500 cells were seeded in six-well plates and allowed to
settle for 32h. Cells were incubated in the indicated chemicals and scattering
was monitored using a phase-contrast  20 objective of an inverted
microscope (Nikon TE2000, Nikon, Surrey, UK) capturing pictures every
10min for 16h.
For knockdown experiments, H1299 cells or HCT116 cells were
transfected with siRNA using hiperfect 24 h after seeding, washed 5 h
later and incubated in 2.5mg/ml ponA (Invitrogen), 10mM U1026 (Sigma,
Gllingham, UK), 10 ng/ml HGF (Sigma) or 25 ng/ml EGF (Sigma) for 48 h as
indicated. For A431 cells and HT-29 cells, nucleofection was used to
knockdown mutant p53 and cells were subsequently plated sparsely in six-
well dishes and incubated with 20 ng/ml HGF for 48 h. Phase-contrast
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images were taken using an Olympus CKX41 microscope, Olympus, East
Grinstead, UK and lysates were harvested for immunoblot analysis to verify
knockdown after scattering. For each condition, 41000 cells from three
independent experiments were counted and tagged as ‘scattered’ or ‘non-
scattered’ in the ImageJ64 plugin ‘cell counter’ to calculate the proportion
of scattered cells. Scattered cells were defined as cells that were growing in
colonies of four cells or less or cells that were touching only one other cell.
Immunohistochemistry
pERK1/2 (p44/42) MAPK ab (9101, Cell Signaling, Danvers, MA, USA; 1:200)
was used to detect mouse pERK1/2 levels and p53 CM-5 (Vector Labs,
Peterborough, UK, VP-P956) was used to detect mouse p53 levels. Both
antibodies underwent pH 6 Na Citrate heat-induced epitope retrieval. The
immunohistochemistryIHC was carried out on paraffin-embedded tis-
sue(obtained as described previously20 using an EnVision kit (Dako,
Hamburg, Germany) according to manufacturer’s instructions.
Inverted Matrigel invasion assay
Matrigel assays were performed as previously described.58 In short,
Matrigel (BD Biosciences, Oxford, UK), supplemented with 25 mg/ml
fibronectin (FN, Sigma) was polymerized in transwell inserts (Corning Life
Sciences, High Wycombe, UK) for 45min at 37 1C. The inserts were inverted
and 2.5 105 cells were seeded at the base of the insert. The remaining
cells were seeded in new dishes and lysates were taken to verify
knockdown. The inserts were placed in serum-free medium and the upper
chamber was filled with 10% FCS and 25 ng/ml EGF, 10 ng/ml HGF, 5 ng/ml
IGF-1 (Sigma) or 10 ng/ml PDGF-b (Sigma). Where necessary, 0.1 nM EGF
inhibitor (PD153035, Calbiochem, Nottingham, UK) and 0.5mg/ml of
integrin-blocking antibodies (Mab16) were added to the Matrigel before
polymerization were necessary and to the medium in all compartments.
Migrating cells were stained in medium containing 4 nM Calcein
(Invitrogen) and were visualized by confocal microscopy (Leica2) in serial
sections of 10mm (or 15 mm for MDA-MB-231 cells) intervals. Quantification
of Matrigel images was performed in ImageJ, in which the intensity of each
slide was measured. Invasion was measured by dividing the sum of the
intensity of all slides beyond 30mm (or 45mm for MDAMB231 cells) by the
sum of the intensity of all slides.
3D reconstruction images and movies of invading 273H H1299 cells
were made by taking pictures in serial sections of 1 mm on the Fluoview
FV1000 confocal microscope (Olympus) using a  40 water lens. The
software program Velocity (Improvision, Coventry, UK) was used to
reconstruct a 3D image and generate movies of invading cells.
AKT/ ERK1/2 activation, immunoprecipitation, ELISA and
immunoblot analyses
Activation of ERK1/2, MET or AKT was determined using phospho-specific
antibodies in western blot. For these assays, cells were serum starved overnight
or 1h and incubated for the indicated times in IGF, PDGF, HGF or EGF (all at
20ng/ml), ponA (2.5mg/ml) or 50nM SU11274 (Selleck, Cambridge, UK). For
transfection experiments, cells were transfected using hiperfect or nucleofec-
tion for knockdown and allowed to reach confluence in approximately 48h.
PonA was added 24h before harvest when necessary and added throughout
the starvation period. Cells were starved for 4h followed by HGF (5ng/ml)
treatment for 10 or 30min as indicated, harvested in cold RIPA lysis buffer and
immediately processed for western blot analysis to detect ERK1/2 phosphor-
ylation. MET phosphorylation was best detected within a time interval of 10min
of HGF exposure after 1h of starvation, whereafter cells were harvested
immediately in sample buffer. RCP co-immunoprecipitation experiments were
performed as described.58 Antibodies to detect the following proteins were
used in western blotting: p53 DO-1 (1:10000, monoclonal65), p53 1801 (1:5000),
pMET (Y1230-1234-1234 1:2000; Millipore), pMET (Y1234, Y1235; 1:1000 Cell
Signaling), pMET (Y1003 1:1000 Abcam), actin (1:5000; Millipore), a5 integrin
(1:1000; BD biosciences), RCP (1:3000; Invitrogen), AKT (1:1000, Cell Signaling),
p-AKT (1:1000, Cell Signaling), ERK1/2 (1:1000, Cell Signaling), pERK1/2 (1:1000,
Cell Signaling), MET (1:250, R&D systems, Abingdon, UK), MET (1:250, R&D
systems, goat), MET (1:1000, Santa Cruz (Santa Cruz, CA, USA), mouse), ZO-1
(1:500, Invitrogen), PAR3 (1:500, Millipore). For measuring HGF in medium, an
ELISA kit (Invitrogen) was used according to the manufacturer’s instructions.
Immunofluorescence
For immunofluorescence, H1299 cells were grown on glass coverslips,
transfected with siRNA using hiperfect and incubated with HGF or ponA as
indicated. A431 cells or HT29 cells were transfected with nucleofection to
knockdown mutant p53 and incubated in HGF where necessary. Cells were
washed with PBS, fixed in 4% paraformaldehyde for 10min in 4 1C and
permeabilized with 0.5% Triton X-100 in PBS for 1min. Cells were washed
four times with PBS and blocked for 30min in 1% BSA (bovine serum
albumin) in PBS, followed by 1h incubation with first antibodies 1% BSA-
PBS. Antibodies were used in the following dilutions: PAR3 (1:75, Millipore),
ZO-1 (1:100, Invitrogen), p53 DO-1 (1:300, monoclonal Cancer Research
UK), E-cadherin (1:125, Cell Signaling), P-Cadherin (1:125, Cell Signaling),
MET (1:50, R&D systems). After three washes with PBS, cells were incubated
with Alexa 488-conjugated or Alexa 594-conjugated secondary antibodies
(Invitrogen, 1:300), supplemented with DAPI (Sigma, 0.5 mg/ml) for 30min.
Cells were rinsed five times with PBS and mounted on microscope slides.
Images were captured using an inverted confocal fluorescent microscope
(Fluoview FV1000, Olympus). Z-stacks were generated with 0.2mm intervals
and E-cadherin in the Z-stacks was quantified by determining the number
of slides in a stack over which a continuous staining of E-cadherin between
two cells could be detected.
Quantitative RT–PCR
For quantitative RT–PCR analyses, RNA was isolated from cells using a
Qiagen kit according to the manufacturer’s instructions. Complementary
DNA was generated using the first-strand cDNA kit from Invitrogen
according to the manufacturer’s instructions on 0.5mg DNAse-treated total
RNA. For the RT–PCR reaction, 5 ml of the 40 times diluted complementary
DNA was used in combination with 10ml Sybr green Mastermix (Thermo
Scientific), 1 ml of each oligo (10mM) and 3 ml H2O with the following PCR
conditions: 94 1C annealing 2min, 40 cycles of 30 s at 94 1C, 30 s at 60 1C
and 1min at 72 1C, followed by a 10-min 72 1C incubation. After finishing
these cycles, a melting curve was generated to check for specificity. mRNA
expression of GAPDH was used as a reference. Oligos: GAPDH fw 50-GCA
GAGATGATGACCCTTTTGGCT-30 ; GAPDH rev 50-TGAAGCTCGGAGTCAACGGAT
TTGGT-30 ; total p63 H1299 cells fw 50-TTCTTAGCGAGGTTGGGCTG-30 , total p63
H1299 cells rev 50-GATCGCATGTCGAAATTGCTC-30 ; TA p63 fw 50-GGACTG-
TATCCGCATGCAG-30 ; TA p63 rev 50-GAGCTGGGCTGTGCGTAG-30 ; dN p63 fw
50-GAAGAAAGGACAGCAGCATTGA-30 ; dN p63 rev 50-GGGACTGGTGGAC
GAGGAG-30 .
Recycling assays
Measurement of integrin recycling has been described previously.59 This
protocol was optimized for MET using 5mg/ml of MET antibody (R&D systems)
to detect levels of biotinylated MET in 50ml lysate by capture enzyme-linked
immunosorbent assays. The quality of the MET antibody to pulldown
biotinylated MET in H1299 cells that were labelled with biotin was determined
in western blots/IPs (immunoprecipitations) in which MET levels and
biotinylated MET (using a streptavidin-HRP antibody to detect MET in the IP
lysate) were determined. Competition experiments to measure the specificity
of the MET antibody for pulldown of biotinylated MET were performed using a
capture enzyme-linked immunosorbent assay.
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